COMPASS THERAPEUTICS, INC. Capital Expenditures Incurred but Not yet Paid
COMPASS THERAPEUTICS, INC. (CMPX) reported Capital Expenditures Incurred but Not yet Paid of $0 for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-03.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2023-08-03
- COMPASS THERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- COMPASS THERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- COMPASS THERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2022-06-30 was $20.00K.
- COMPASS THERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2022-03-31 was $57.00K, a 64.60% decline year-over-year.
- COMPASS THERAPEUTICS, INC. capital expenditures incurred but not yet paid for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- COMPASS THERAPEUTICS, INC. capital expenditures incurred but not yet paid for fiscal 2021 was $187.00K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $0.00 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-04 | ||
| 2022-12-31 | $0.00 10-K · filed 2023-03-15 | ||
| 2022-06-30 | $20.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $77.00K 10-Q · filed 2023-08-03 | |
| 2022-03-31 | $57.00K 10-Q · filed 2023-05-04 | ||
| 2021-12-31 | $187.00K 10-K · filed 2023-03-15 | ||
| 2021-06-20 | -$161.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-01 | $0.00 10-Q · filed 2022-08-01 | |
| 2021-03-31 | $161.00K 10-Q · filed 2022-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |